BIOtech Now Dan Durham In a story entitled, “CMS Blames Medicare Part B Hikes on Drug Costs,” writers for Politico Pulse note: “The agency [Centers for Medicare & Medicaid Services] on Friday announced a $9 monthly premium increase and $13 annual deductible hike, but argued that the White House is working to bring down cost […]

BIOtech Now Brian Newell Supporters of Speaker Pelosi’s extreme drug pricing bill (H.R. 3) want us to believe that they can destroy the biopharmaceutical industry and still produce new cures and treatments for patients in need. The crux of this fairy tale is the promise by supporters of H.R. 3 to reinvest “savings” from the […]

BIOtech Now Theresa Brady Representing all facets of the patient stakeholder community, participants in BIO’s eighth Patient and Health Advocacy Summit (#BIOSummit19) came together to proclaim: “I am BIO.” But as Dr. Julie Gerberding, executive vice president and chief patent officer at Merck and Co., who acted as the event’s chief convener, added: “I am […]

BIOtech Now Andrew Segerman Writing for Morning Consult, BIO’s Jim Greenwood discusses the challenges of developing novel antibiotics and highlights the urgent need for policies that incentivize innovators to produce new ones. “The reason why so few antibiotics are being developed is simple – the market is broken. Estimates show that it takes more than a […]

BIOtech Now Rufael Seyum Since its inception 17 years ago, the BIO Investor Forum has become the premier event where biotech innovators can find investors and strategic partners to advance their company to the next stage in their business life cycle. Over the past two days, more than 340 private equity and public investors from […]

BIOtech Now Rufael Seyum Confusion among Chinese investors about shifting U.S. regulatory policy is draining billions of dollars from the American biotechnology sector and stressing startups that rely on foreign capital to cure disease. That was the message of James Huang, a managing partner in Kleiner Perkins’s China office who specializes in facilitating cross-border deal financing. […]

BIOtech Now Jim Greenwood On behalf of the team at BIO, we send our deepest condolences to the family of Dr. John Holaday who tragically passed away. Dr. Holaday’s career was nothing short of inspiring. After earning his Ph.D. from the University of California, San Francisco School of Medicine, he served at the Walter Reed […]

BIOtech Now Andrew Segerman The Subcommittee on Consumer Protection and Commerce of the Committee on Energy and Commerce is set to examine the U.S. patent system this morning. Ahead of the hearing – and in honor of #ThrowBackThursay – we are resurfacing a piece by BIO’s Tom DiLenge that helps debunk some of the most common […]

BIOtech Now Andrew Segerman The Trump Administration is moving forward with a plan to import foreign price controls into Medicare. Under the proposed International Pricing Index (IPI) model, the federal government would move away from a long-standing market-based reimbursement system to one that is tied to prices paid in countries with single-payer health care systems. […]

BIOtech Now Andrew Segerman Writing for the Boston Globe, Dr. Michael Rosenblatt, chief medical officer of the venture firm Flagship Pioneering, debunks the common myth that biopharmaceutical companies are “free-riding” on government research. Policymakers in Washington have long preferred to believe that scientists and researchers funded by federal taxpayer dollars discover medicines on their own, […]

BIOtech Now Andrew Segerman Transformative therapies are advancing like never before, and a new class of medicines are changing the way we treat the world’s most devastating and debilitating diseases. Yet while innovative biopharmaceutical companies are doing their part in developing lifesaving products for patients, discriminatory insurance barriers are often standing in the way. Insurance […]

BIOtech Now Andrew Segerman Writing for Morning Consult, Dr. Judy Monroe, president and CEO of the CDC Foundation, highlights the importance of immunization as August marks National Immunization Awareness Month. “As an international public health community, we have eradicated the scourge of smallpox thanks to Edward Jenner’s research and the development of the world’s first […]

BIOtech Now Nareg Sagherian As the biopharma industry has gained traction on new drug approvals throughout 2019, the financial dollars have followed suit.  According to BIO’s 2019 Emerging Therapeutic Company Trend Report, a record $17.5 billion in venture investment dollars went to emerging therapeutic companies globally in 2018.  In 2018, venture capital funding of private […]

BIOtech Now Andrew Segerman The Biotechnology Innovation Organization (BIO), leading scientists, public policy experts, and industry leaders today announced the launch of “Working to Fight AMR,” a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance and advocate for policies that accelerate the creation of new medicines. Each year, it […]

BIOtech Now Andrew Segerman BIO’s Jim Greenwood joined CSPAN’s Washington Journal for a conversation about drug pricing, the latest proposals being considered on Capitol Hill, the need to sustain biomedical innovation, and ways to ensure patients have access to the medicines they need with out-of-pocket costs they can afford. Watch the full segment below. Full […]

BIOtech Now Andrew Segerman Writing for STAT News, Paul Hastings – CEO of Nkarta Therapeutics and Vice Chair of BIO’s Board – warns that bad actors in the sector, as well as shortsighted proposals in Washington DC, threaten to derail a coming wave of biomedical innovation. Biomedical innovation is currently being jeopardized by a well-publicized […]

BIOtech Now Andrew Segerman BIO is out with a new whiteboard video that explores why more and more patients are facing higher costs when they go to the pharmacy to buy their prescription drugs. See how rebates and discounts within the drug cost ecosystem are often not used by insurers to lower patients’ out-of-pocket drug […]